Drugs / ABT-436
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01380704 | Jun → Sep 2011 | major depressive disorder | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01050127 | Dec 2009 → Feb 2010 | — | Abbott | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01741142 | Jan 2012 → Oct 2013 | major depressive disorder | AbbVie | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01613014 Comparator | Feb 2013 → May 2015 | alcohol abuse, alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-436 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01613014 ↗ |
| Action | Inhibit | “The V1B antagonist ABT-436” PMID 28293470 ↗ Feb 2017 |